Physician profile
Natalia Hedges
NPI 1881268514
$958.81
in general payments reported to CMS, 2019-2025
22 companies · $580 in 2025
The $580 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $107 · 2024: $271 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.66 | 2025 | Caplyta |
| Lilly USA, LLC | $107.57 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $103.69 | 2024-2025 | |
| Abbvie INC. | $99.04 | 2023-2025 | |
| Axsome Therapeutics, INC. | $87.77 | 2024-2025 | Sunosi, Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.40 | 2025 | Jardiance |
| Tris Pharma INC | $61.51 | 2025 | Dyanavel Xr |
| Inspire Medical Systems, INC. | $47.08 | 2023-2024 | Inspire |
| Dynavax Technologies Corporation | $45.06 | 2023-2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $30.11 | 2024-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $28.92 | 2023-2024 | Arexvy, Shingrix |
| Organon LLC | $23.19 | 2024-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $18.47 | 2025 | Vaxelis, Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $16.30 | 2024 | |
| Amgen INC. | $15.01 | 2024 | Prolia, Evenity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $14.97 | 2024 | Wegovy |
| Si-Bone, INC. | $14.78 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $13.98 | 2025 | Rexulti |
| Exeltis, USA INC. | $13.63 | 2025 | Slynd |
| Harmony Biosciences LLC | $13.58 | 2025 | |
| Sanofi-Aventis U.S. LLC | $13.53 | 2025 | |
| Phathom Pharmaceuticals, INC. | $11.56 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Hedges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.